GlassScriptPhysician profile
Isaac Mohr
NPI 1346724820
$2,961.93
in general payments reported to CMS, 2019-2025
30 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $893 · 2023: $992 · 2024: $540 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,004 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.03 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $495.22 | 2022-2025 | Xtandi, Myrbetriq, Veozah |
| Teleflex LLC | $438.05 | 2022-2025 | Urolift, Barrigel |
| Astrazeneca Pharmaceuticals LP | $309.28 | 2022-2024 | Lynparza |
| Urovant Sciences INC | $189.61 | 2022 | |
| Pfizer INC. | $138.74 | 2022-2024 | |
| Procept Biorobotics Corporation | $133.17 | 2025 | |
| Progenics Pharmaceuticals, INC. | $119.58 | 2022-2025 | Pylarify |
| Merck Sharp & Dohme LLC | $112.06 | 2022-2023 | Lynparza, Keytruda, Welireg |
| Axonics, INC. | $105.11 | 2024 | Axonics |
| Urogen Pharma, INC. | $99.46 | 2023-2025 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $82.95 | 2022-2023 | |
| Agiliti Surgical, INC. | $72.93 | 2023 | Soltive, Trinity, Sonablate |
| Convatec INC. | $71.41 | 2022 | |
| Dendreon Pharmaceuticals LLC | $68.37 | 2024 | Provenge |
| Janssen Biotech, INC. | $64.72 | 2023 | Erleada, Akeega |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $58.94 | 2023 | Orgovyx, Gemtesa |
| Foundation Medicine, INC. | $49.14 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $47.77 | 2022-2023 | |
| Myovant Sciences INC. | $40.15 | 2022 | |
| Accord Healthcare, INC. | $33.40 | 2022-2023 | |
| Tolmar Pharmaceuticals, INC. | $29.00 | 2022 | |
| Olympus America INC. | $28.53 | 2025 | Itind System |
| Civco Medical Instruments | $27.94 | 2025 | |
| Tolmar, INC. | $26.63 | 2024 | |
| 180 Medical, INC. | $25.14 | 2023 | |
| Novo Nordisk INC | $24.87 | 2024 | |
| Abbvie INC. | $21.45 | 2024 | |
| Ethicon US, LLC | $18.59 | 2025 | Stratafix, Echelon Flex, Monocryl |
| Myriad Genetic Laboratories, INC. | $15.75 | 2023 | Prolaris |
| Amgen INC. | $13.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Mohr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.